Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Drug discovery company C4X Discovery has appointed Simon Harford, who has previously worked at GSK and Eli Lilly, to its board.
Harford, who is chief executive of Albireo Pharma, has joined as a non-executive director with immediate effect.
He was previously CFO of Parexel International and, prior to this, held various financial leadership roles at GSK as well as key financial management roles at Eli Lilly and Company.
Chairman Eva-Lotta Allan said: 'Simon brings a wealth of global pharmaceutical expertise across key financial markets, including the US where he is based.
'His deep understanding of global pharmaceutical financial strategy will be invaluable as we continue to grow C4XD and expedite major out-licensing deals such as our recent deals with Sanofi and Indivior.'
At 3:02pm: (LON:C4XD) C4x Discovery Holdings Plc share price was 0p at 23.8p